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Abstract
Background: This study investigated the cardiovascular (CV) safety profile of the dipeptidyl peptidase (DPP)-4
inhibitor linagliptin versus comparator treatments.
Methods: This was a pre-specified meta-analysis of CV events in linagliptin or comparator-treated patients with
type 2 diabetes mellitus (T2DM) from eight Phase 3 studies. All suspected CV events were prospectively
adjudicated by a blinded independent expert committee. The primary endpoint was a composite of CV death,
stroke, myocardial infarction, and hospitalization for unstable angina. Three secondary composite endpoints derived
from the adjudicated CV events were also pre-specified. Risk estimates were calculated using several statistical
methods including Cox regression analysis.
Results: Of 5239 treated patients (mean ± SD HbA1c 65 ± 10 mmol/mol [8.0 ± 0.9%], age 58 ± 10 years, BMI 29 ±
5 kg/m
2), 3319 received linagliptin once daily (5 mg, 3159; 10 mg, 160) and 1920 received comparators (placebo,
977; glimepiride 1-4 mg, 781; voglibose 0.6 mg, 162). Cumulative exposure (patient-years) was 2060 for linagliptin
and 1372 for comparators. Primary CV events occurred in 11 (0.3%) patients receiving linagliptin and 23 (1.2%)
receiving comparators. The hazard ratio (HR) for the primary endpoint showed significantly lower risk with
linagliptin than comparators (HR 0.34 [95% confidence interval (CI) 0.16-0.70]) as did estimates for all secondary
endpoints (HR ranging from 0.34 to 0.55 [all upper 95% CIs < 1.0]).
Conclusions: These results from a large Phase 3 programme support the hypothesis that linagliptin may have CV
benefits in patients with T2DM.
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Background
Despite continuing medical and pharmacological efforts,
patients with type 2 diabetes mellitus (T2DM) still bear
a substantial burden of increased cardiovascular (CV)
morbidity and premature mortality [1,2]. Although
many risk factors are involved, hyperglycaemia remains
an important contributor to increased CV disease inci-
dence and seems to potentiate the deleterious effects of
lipids and blood pressure elevation [2,3]. Nonetheless,
recent large outcomes trials of glycaemic intervention in
general and of intensive treatment in particular have
shown conflicting results in terms of CV benefits for
patients with T2DM [4-7]. The ambivalence of these
findings has led to development of the hypothesis that
the effectiveness of intensive glucose control likely
depends on individualizing treatment (e.g. treatment
modality and glycaemic target) to account for CV risk
and other factors [8]. In particular, weight gain and
increased hypoglycaemia are often associated with estab-
lished glucose-lowering treatments that increase insulin
secretion (in a glucose-independent manner) or insulin
sensitivity and may heighten CV risk. Some agents, such
as rosiglitazone, have been shown to increase risk for
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effects [9]. In light of these concerns, regulatory authori-
ties, including the US Food and Drug Administration
(FDA) and the European Medicines Agency, have issued
guidance that the development programmes for all new
glucose-lowering therapies must show that treatment
confers no unacceptable increases in CV risk [10,11].
The need to improve glycaemic control while mini-
mizing harmful side effects has led to interest in thera-
peutic approaches aimed at avoiding such pitfalls.
Dipeptidyl peptidase (DPP)-4 inhibitors, which enhance
postprandial levels of the incretin hormones glucagon-
like peptide (GLP)-1 and glucose-dependent insulinotro-
pic polypeptide (GIP), have limited side effects [12]. The
glucoregulatory actions of incretins include glucose-
dependent promotion of insulin secretion, glucagon sup-
pression, delayed gastric emptying, and increased satiety.
Linagliptin is a DPP-4 inhibitor that was recently
approved as a once-daily oral glucose-lowering drug in
the USA, Japan, and Europe. Its molecular structure is
xanthine-based, which differs from that of other DPP-4
inhibitors. Linagliptin has pharmacokinetic properties
that confer a prolonged terminal half-life (t1/2 >1 0 0h ) ,
and potent and durable DPP-4 inhibition (maximal inhi-
bition of > 90% and inhibition 24 h after dosing of ~
85% with linagliptin 5 mg at steady state); and unlike
other DPP-4 inhibitors, it is primarily excreted via bile
and the gut [13-15]. In Phase 3 trials, linagliptin has
demonstrated clinically meaningful glycaemic efficacy
and favourable safety/tolerability compared with placebo
as monotherapy or in combination with metformin,
metformin plus sulphonylurea, or pioglitazone [16-19].
To thoroughly determine the CV safety of linagliptin,
we undertook a meta-analysis of the CV risk associated
with linagliptin versus placebo or active comparators in
patients with T2DM participating in the linagliptin
Phase 3 study programme. This was a pre-specified
meta-analysis in which suspected CV events were pro-
spectively captured and adjudicated in a blinded fashion
by an independent CV expert committee.
Methods
Study selection
The current meta-analysis included all randomized, dou-
ble-blind, placebo- or active-controlled Phase 3 trials of
linagliptin of > 12 weeks duration for which the data-
base lock for the interim or final analyses was completed
on or before 16 February 2010. This included eight stu-
dies that assessed linagliptin 5 mg or 10 mg/day versus
placebo, glimepiride 1-4 mg/day, or voglibose 0.6 mg/
day over 18-52 weeks as monotherapy or in combina-
tion with various common background therapies (for
further details see Additional file 1, or the individual
study publications [16-19]).
All patients from each study provided written
informed consent. Local ethics committees/institutional
review boards reviewed and approved all study proto-
cols. All studies were conducted within ethical standards
and in accordance with the Declaration of Helsinki and
any applicable regulatory requirements.
Analysis population
Common criteria across the Phase 3 trials included a
diagnosis of inadequately controlled T2DM, age ≥ 18
years and, in most studies, body mass index (BMI) ≤ 40
kg/m
2. Background medication with metformin was
mandatory except where inclusion criteria required
treatment-naïve patients, metformin-ineligible patients,
or washout of pre-existing oral glucose-lowering drugs
(including metformin). In all studies, rescue medication
was provided with pioglitazone and/or insulin dose
adjustment or supplementation for glycaemic deteriora-
tion, triggered by plasma glucose levels measurement on
two separate occasions of > 13.3, > 11.1, or > 10.0
mmol/L after overnight fasts during the first 12, 12-24,
or > 24 weeks, respectively.
CV event data collection and adjudication
Adverse events (AEs) were captured and collected on-
site by the study investigators using electronic case
report forms. AEs were then mapped to preferred terms
according to the Medical Dictionary for Regulatory
Activities (MedDRA). A pre-specified list of trigger
events (the Standard MedDRA Queries for ischaemic
heart disease and cerebrovascular disorders) and all fatal
events were identified for adjudication. In patients with
a trigger event, an individual patient data package
(patient profile and all available cardiology or neurology
tests, laboratory tests, and medical records) was pre-
pared for the adjudication committee. A cardiology or
neurology clinical event committee, based on the data
package, without knowledge of the treatment allocation,
adjudicated on the trigger event and recorded the type
of event as appropriate. These adjudicated events were
collected and included in the clinical trial database upon
completion of database lock for the full or interim
analyses.
Study endpoints
The primary endpoint was a composite of CV death
(including fatal stroke and fatal myocardial infarction
[MI]), non-fatal stroke, non-fatal MI, and hospitalization
for unstable angina pectoris (UAP). Secondary endpoints
were composites of: (i) CV death, non-fatal stroke, and
non-fatal MI; (ii) all adjudicated CV events which
included CV death, non-fatal stroke, non-fatal MI, UAP
with or without hospitalization, stable angina pectoris
(SAP), and transient ischaemic attacks (TIA); and (iii)
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derived from 34 unadjudicated MedDRA preferred
terms for stroke and MI. Tertiary endpoints were the
individual adjudicated components (as listed above) and
total mortality.
Statistical analysis
Analyses were based on individual patient data in the
treated set, which was defined as all patients who were
randomized and received at least one dose of study
medication, in all Phase 3 studies. Descriptive statistics
(incidence and incidence rates per 1000 patient-years)
were determined for all endpoints in each of the pooled
treatment groups within the treated set.
The primary analyses assessed the CV risk for all pri-
mary, secondary, and tertiary endpoints associated with
linagliptin versus total comparators. Risk estimates were
calculated using several common statistical methods
that included: (i) the hazard ratio (HR) for time to first
event calculated using the Cox proportional hazards
model with adjustments for study and treatment group;
(ii) the incidence-rate risk ratio (RR) for time to first
event calculated using Poiss o nr e g r e s s i o nw i t ha d j u s t -
ment for study and treatment group; (iii) the odds ratio
(OR) for occurrence of events calculated using a strati-
fied Exact test; and (iv) the RR for occurrence of events
calculated using a stratified Cochran-Mantel-Haenszel
(CMH) test with continuity correction for trials with
zero events.
Sensitivity analyses included evaluation of the primary
endpoint associated with linagliptin versus total com-
parators in pre-specified subgroups based on age, gen-
der, race, and use of rescue medication, as well as
further exploratory subgroups based on occurrence of
hypoglycaemia and Framingham 10-year CV risk score.
In addition, a post hoc analysis of the primary endpoint
assessed events in linagliptin- and placebo-treated
patients, taken only from placebo-controlled trials and
placebo-controlled periods within trials. In addition, the
influence on the primary endpoint of the factors: study,
treatment, gender, race and time since diagnosis of dia-
betes, was investigated using Cox regression.
This combined study analysis was developed to fully
adhere to the recent FDA guidance on assessment of
CV safety for the development of oral glucose-lowering
drugs [11].
Results
Patient characteristics and drug exposure
The current analysis included eight trials with a total of
5239 treated patients: 3319 received linagliptin once
daily (5 mg: n = 3159, 10 mg: n = 160) and 1920 com-
parators (placebo: n = 977, glimepiride: n = 781, and
voglibose: n = 162) (see Additional file 1). Patients were
followed for a median (min, max) period of 175 (1, 617)
days for linagliptin and 179 (1, 619) days for total com-
parators (169 [1, 367] for placebo and 409 [3, 619] for
active comparators). Cumulative exposure (patient-
years) was 2060 for linagliptin and 1372 for total com-
parators (422 for placebo, 872 for glimepiride, and 78
for voglibose).
T h eo v e r a l lm e a n( ±S D )a g e ,B M I ,a n dH b A 1 cw e r e
58 ± 10 years, 29 ± 5 kg/m
2, and 64 ± 10 mmol/mol
(8.0 ± 0.9%), respectively, and 52.4% of patients had
known T2DM for > 5 years. The predominant race was
w h i t e( 6 0 . 5 % ) ,a n dt h e r ew e r em o r em a l e s( 5 5 . 5 % )t h a n
females. In total, 60.8% of patients had metabolic syn-
drome (based on the International Diabetes Federation
definition), 10.6% coronary artery disease, 2.5% cerebro-
vascular disease, and 3.3% peripheral artery disease. In
addition, 64.6% of patients were hypertensive, and 38.3%
were current or ex-smokers. The prevalence of some
degree of renal impairment was 24.2% or 44.6% of all
patients, according to the Cockcroft-Gault (CG) or
Modification of Diet in Renal Diseases (MDRD) formu-
lae, respectively. In general, these baseline demographics
and clinical characteristics were comparable between the
linagliptin and comparator groups (Tables 1 and 2).
Table 3 shows changes from baseline to last measure-
ment for HbA1c, systolic and diastolic blood pressure
(BP), total cholesterol, triglycerides and body weight for
the pooled linagliptin and the pooled comparator group.
Changes were of similar magnitude in both groups for
all parameters except for HbA1c, where a meaningful
HbA1c reduction was seen for linagliptin, and body
weight, where a modest weight increase was seen in the
total comparator group. These findings were expected
since linagliptin is a glucose-lowering drug and were
provided to all patients in the linagliptin group, whereas
~50% of patients in the comparator cohort received
placebo.
Adjudicated CV events
Table 4 summarizes the incidence of each CV endpoint.
Overall, adjudicated primary CV events occurred in 11
(0.3%) patients receiving linagliptin and 23 (1.2%) receiv-
ing comparators (3 on placebo, 20 on glimepiride, and
none on voglibose). Notably, the main contributor to
the overall differences in incidence of the primary end-
point was the events in the head-to-head study of lina-
gliptin versus glimepiride (mean ± SD dose of
glimepiride at week 52: 3.0 ± 1.2 mg).
Linagliptin treatment versus comparators was asso-
ciated with reduced CV risk for the primary endpoint.
The HR for the primary endpoint indicated a significant
risk reduction, as did the OR and RR, for linagliptin ver-
sus comparator (i.e. upper bound of 2-sided 95% confi-
dence interval [CI] < 1.0) (Figure 1). The difference in
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mately 8 weeks and did not tend to plateau thereafter
(Figure 2). Further analysis of the primary endpoint for
linagliptin against placebo in those patients taken from
the same placebo-controlled trials confirmed that lina-
gliptin was associated with no significantly increased
risk for the primary endpoint. The HR, OR, and RR
with linagliptin versus placebo ranged from 0.69 to 0.90,
but all had upper limits of 95% CIs that included 1.0.
The incidence rates for the primary endpoint and the
associated CV risk reductions with linagliptin versus
comparators in a number of subgroups (based on age,
gender, race, rescue medication use, hypoglycaemia
occurrence, or Framingham CV risk score) were gener-
ally consistent with the results in the overall population
(Table 5 and Additional file 2). There were no signifi-
cant increases in risk based on the HR and RR for the
primary endpoint with linagliptin relative to compara-
tors in any subgroup. However, linagliptin did achieve
significant risk reductions over comparators in several
subgroups, including males, whites, those receiving no
rescue medication, those reporting no hypoglycaemia,
and those with higher CV risk (Framingham CV risk
score > 15%). Further, in the Cox regression analysis the
HR was 0.36 (95% CI: 0.17-0.74) in a model where
study, treatment, gender, race and time since diagnosis
of diabetes were taken into account, i.e., fully in line
with the HR seen in the simple Cox model (0.34).
The HRs for all secondary endpoints indicated signifi-
cantly lower CV risk with linagliptin than comparators
(Figure 3). Similarly, significant ORs and RRs for linaglip-
tin versus total comparators were also observed, with the
single exception of the RR for all adjudicated CV events
when evaluated with CMH method, where the upper 95%
CI was equal to 1.0 (see Additional file 3). Of the tertiary
endpoints, most HRs with linagliptin versus comparators
showed either a favourable trend for risk reduction, as in
the case of CV death, non-fatal MI, UAP, and TIA, or
neutrality, as in the case of SAP and total deaths (Table
6); one exception was non-fatal stroke which was signifi-
cantly lower with linagliptin versus comparators. Similar
observations were made for OR and RR for linagliptin
versus total comparators (see Additional file 3).
Discussion
This CV meta-analysis indicates that linagliptin may
have a beneficial or neutral impact on CV outcomes in
a large population of patients with T2DM compared
with control treatments. Furthermore, the risk for CV
events was unchanged, or lowered, across a number of
pre-specified subgroups based on key demographic and
clinical characteristics. These results include compari-
sons with placebo, as well as two active comparators,
namely glimepiride (a second-generation sulphonylurea
frequently used as second-line therapy in the USA and
Europe) and voglibose (an a-glucosidase inhibitor com-
monly used in Asia), either as monotherapy or in com-
bination with common oral glucose-lowering drugs.
Table 1 Baseline demographics and clinical
characteristics of the pooled cohorts from 8 trials of
linagliptin versus total comparators (placebo and active
treatment)
Linagliptin
(n = 3319)
Total comparators
(n = 1920)
Gender, % of patients
Male/female 53.7/46.3 58.6/41.4
Age, years 58 ± 10 58 ± 10
BMI, kg/m
2 28.8 ± 5.0 29.1 ± 4.9
Race, % of patients
White 59.7 61.8
Black 1.4 1.6
Asian 38.9 36.6
HbA1c, mmol/mol 65 ± 10 64 ± 10
HbA1c, % 8.1 ± 0.9 8.0 ± 0.9
FPG, mmol/L 9.3 ± 2.4 9.4 ± 2.3
Diabetes duration (known), % of patients
≤ 1 years 12.1 12.2
1-5 years 34.8 36.6
> 5 years 53.1 51.2
Previous oral glucose-lowering agents, % of patients
None 17.3 17.3
1 42.8 49.9
2 39.7 32.5
≥ 3 0.2 0.2
CV risk factors, % of patients
Metabolic syndrome* 60.3 61.7
Coronary artery disease 10.4 11.0
Cerebrovascular disease 2.9 3.9
Peripheral artery disease 2.3 3.0
Hypertension 63.8 66.0
Ex-/current smoker 22.9/14.4 24.2/15.9
eGFR using CG/MDRD formulae, % of patients
Normal 74.9/55.4 77.3/55.4
Mildly impaired 19.9/37.3 18.5/38.1
Moderately impaired 2.2/4.3 1.9/4.3
Severely impaired 0.1/0.1 0.1/0.1
CV medication, % of patients
Acetyl-salicylic acid 29.5 30.5
Antihypertensive 60.0 63.0
Lipid-lowering therapy 39.5 42.1
Any of the above 72.8 75.5
Framingham 10-year CV risk score
Score, % 9.8 ± 8.2 10.3 ± 8.4
Score > 15%, % of patients 27.8 31.1
*International Diabetes Federation definition. Values are mean ± SD, unless
otherwise stated. BMI, body mass index; CG, Cockcroft-Gault; CV,
cardiovascular; eGFR, estimated glomerular filtration rate; FPG, fasting plasma
glucose; MDRD, Modification of Diet in Renal Disease study.
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tion were generally comparable to those reported in gen-
eral T2DM populations. In this study, mean age was 58
years, BMI was 29 kg/m
2, and 44.5% were females com-
pared with age of 60 years, BMI of 32 kg/m
2,a n d5 2 . 4 %
females in the US National Health and Nutrition Exami-
nation Survey (NHANES) in 2003-2004 [20]. In this
study versus the 2002 Cost of Diabetes in Europe
(CODE)-2 study, the prevalence of previous MI was
10.6% versus 9.0% and of previous stroke was 2.5% versus
5% [21]. Furthermore, in the current study population,
44.6% had some degree of renal impairment versus 43.8%
of those with self-reported T2DM in the NHANES popu-
lation in 2009 (based on the MDRD equation) [22].
The incidence rates for CV events in this meta-analy-
sis of linagliptin Phase 3 trials were relatively consistent
Table 2 Baseline demographics and clinical characteristics for the subset cohorts of patients participating in either
placebo controlled trials or active controlled trials
Active controlled trials (n = 2) Placebo controlled trials (n = 6)
Linagliptin (n = 1097) Active comparators* (n = 943) Linagliptin (n = 2541)
† Placebo (n = 977)
Gender, % of patients,
Male/female 62.4/37.6 62.8/37.2 51.9/48.1 54.7/45.3
Age, years 60 ± 10 60 ± 10 58 ± 10 57 ± 10
BMI, kg/m
2 28.6 ± 5.1 29.5 ± 4.8 28.4 ± 5,0 28.7 ± 5.0
Race, % of patients
White 60.2 69.9 52,0 54.0
Black 1.8 1.9 1.0 1.3
Asian 38.0 28.2 47.0 44.6
HbA1c, mmol/mol 62 ± 9 62 ± 10 66 ± 9 66 ± 10
HbA1c, % 7.8 ± 0.8 7.8 ± 0.9 8.2 ± 0.8 8.2 ± 0.9
FPG, mmol/L 9.1 ± 2.2 9.2 ± 2.3 9.4 ± 2.3 9.5 ± 2.3
Diabetes duration (known), % of patients
≤ 1 years 8.1 8.4 13.8 16.0
1-5 years 40.6 38.8 32.7 34.4
> 5 years 51.3 52.8 53.6 49.6
Ex-/current smoker 29.6/17.6 29.5/15.7 21.1/14.7 19.1/16.1
eGFR using CG/MDRD formulae, % of patients
Normal 76.2/59.3 78.0/52.3 73.4/57.3 76.7/58.3
Mildly impaired 20.6/35.5 18.7/41.4 20.8/35.3 18.3/34.9
Moderately impaired 1.6/3.7 1.1/4.1 2.6/4.3 2.7/4.5
Severely impaired 0/0 0/0 0.1/0.1 0.2/0.1
Framingham 10-year CV risk score
Score, % 11.5 ± 8.1 11.6 ± 8.6 9.2 ± 8.0 9.1 ± 8.1
Score > 15%, % of patients 34.9 37.8 25.3 24.7
*Glimepiride (n = 781), voglibose (n = 162),
†One phase 3 trial was both placebo controlled (for the first 12 weeks) and actively controlled (for the first 26 weeks)
and therefore the included 319 linagliptin patients are presented in both parts of the table. Values are mean ± SD, unless otherwise stated. BMI, body mass index;
CG, Cockcroft-Gault; CV, cardiovascular; eGFR, estimated glomerular filtration rate; FPG, fasting plasma glucose; MDRD, Modification of Diet in Renal Disease study.
Table 3 Changes in CV risk factors from baseline to last measurement in the pooled cohorts of 8 trials of linagliptin
versus total comparators (placebo and active treatment)
Pooled linagliptin Pooled total comparators
Baseline Study end Baseline Study end
HbA1c , mmol/mol 64 ± 10 58 ± 11 63 ± 10 60 ± 13
HbA1c, % 8.1 ± 0.9 7.5 ± 1.0 8.0 ± 0.9 7.7 ± 1.2
Systolic BP, mmHg 131 ± 15 130 ± 15 132 ± 15 132 ± 15
Diastolic BP, mmHg 79 ± 9 78 ± 9 79 ± 9 79 ± 9
Total cholesterol, mmol/L 4.6 ± 0.6 4.6 ± 0.6 4.6 ± 0.6 4.7 ± 0.6
Triglycerides, mmol/L 2.6 ± 1.8 2.5 ± 1.8 2.6 ± 1.9 2.6 ± 1.9
Body weight, kg 78.9 ± 17.7 78.9 ± 17.6 81.0 ± 17.4 81.6 ± 17.9
Values are mean ± SD. BP, blood pressure.
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other DPP-4 inhibitors’ clinical trial programmes. The
incidence rates (per 1000 patient-years) for the primary
CV endpoint were 5.3 for linagliptin versus 16.8 for
total comparators. In comparison, other CV meta-ana-
lyses reported incidence rates for custom MACE ranging
from 5.8 to 14.6 with sitagliptin, saxagliptin, or vildaglip-
tin and 9.0 to 14.1 with comparators [23-25].
Table 4 Incidence and incidence rates of primary, secondary, and tertiary endpoints
Linagliptin
(n = 3319)
Active comparators*
(n = 943)
Placebo
(n = 977)
Total comparators
(n = 1920)
Incidence
n (%)
Incidence rate
(per 1000
years)
Incidence
n (%)
Incidence rate
(per 1000
years)
Incidence
n (%)
Incidence rate
(per 1000
years)
Incidence
n (%)
Incidence rate
(per 1000
years)
Primary endpoints:
CV death, stroke, MI,
or UAP with
hospitalization
11 (0.3) 5.3 20 (2.1) 21.2 3 (0.3) 7.0 23 (1.2) 16.8
Secondary endpoints:
CV death, stroke, or
MI
10 (0.3) 4.8 18 (1.9) 19.1 2 (0.2) 4.7 20 (1.0) 14.6
All major CV events 26 (0.8) 12.6 26 (2.8) 27.6 6 (0.6) 14.1 32 (1.7) 23.4
FDA-custom MACE 9 (0.3) 4.3 16 (1.7) 16.9 3 (0.3) 7.0 19 (1.0) 13.9
Tertiary endpoints:
CV death 2 (0.06) 1.0 2 (0.2) 2.1 0 0 2 (0.1) 1.5
MI 6 (0.2) 2.9 6 (0.6) 6.3 1 (0.1) 2.3 7 (0.4) 5.1
Stroke 2 (0.06) 1.0 10 (1.1) 10.6 1 (0.1) 2.3 11 (0.6) 8.0
TIA 1 (0.03) 0.5 3 (0.3) 3.2 1 (0.1) 2.3 4 (0.2) 2.9
UAP with
hospitalization
1 (0.03) 0.5 2 (0.2) 2.1 1 (0.1) 2.3 3 (0.2) 2.2
UAP without
hospitalization
1 (0.03) 0.5 1 (0.1) 1.1 0 0 1 (0.05) 0.7
SAP 13 (0.4) 6.3 5 (0.5) 5.3 3 (0.3) 7.0 8 (0.4) 5.8
Total mortality 4 (0.1) 1.9 3 (0.3) 3.2 0 0 3 (0.2) 2.2
*Glimepiride (n = 781), voglibose (n = 162).
CV, cardiovascular; FDA, Food and Drug Administration; MACE, major adverse CV events; MI, myocardial infarction; SAP, stable angina pectoris; TIA, transient
ischaemic attack; UAP, unstable angina pectoris.
Figure 1 Risk estimates for primary composite CV endpoint with linagliptin versus total comparators based on various statistical
models. CI, confidence interval; CMH, Cochran-Mantel-Haenszel; CV, cardiovascular; HR, hazard ratio; OR, odds ratio; RR, risk ratio.
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relative risk for CV outcomes with DPP-4 inhibitors ver-
sus comparators that were below 1.0. However, not all
of these risk estimates achieved statistical significance
(based on upper bounds of 95% CI below 1.0). Risk
reductions were significant in the present meta-analysis
of linagliptin [HR 0.34 (95% CI 0.16-0.70)] and in the
previous analysis of saxagliptin 2.5-10 mg [HR 0.43
(95% CI 0.23-0.80)] [23]. In contrast, risk estimates were
non-significant for sitagliptin 100 mg [RR 0.68 (95% CI
0.41-1.12)] and vildagliptin 50 mg and 100 mg [RR 0.84
(95% CI 0.64-1.14) and 0.88 (95% CI 0.37-2.11)] [24,25].
Figure 2 Time to occurrence of primary composite CV event with linagliptin versus total comparator.
Table 5 Subgroup analyses of primary endpoint for linagliptin versus total comparators based on Cox hazard model
and CMH test
Linagliptin, patients with events/total
patients
Total comparators, patients with events/total
patients
Cox HR (95%
CI)
CMH RR (95%
CI)
Age (years)*
< 65 6/2390 9/1371 0.40 (0.14-1.14) 0.49 (0.19-1.27)
≥ 65 5/929 14/549 0.28 (0.10-0.79) 0.43 (0.18-1.03)
Gender
Male 7/1782 20/1126 0.25 (0.10-0.60) 0.31 (0.13-0.71)
Female 4/1537 3/794 0.96 (0.21-4.37) 1.00 (0.32-3.17)
Race
White 8/1981 22/1187 0.28 (0.12-0.63) 0.32 (0.15-0.70)
Black 0/46 0/31 n.a. 1.00 (0.29-3.50)
Asian 3/1292 1/702 1.63 (0.17-15.7) 1.20 (0.34-4.26)
Use of rescue medication
No 8/3006 20/1666 0.29 (0.12-0.66) 0.37 (0.17-0.80)
Yes 3/313 3/254 0.80 (0.16-3.96) 0.91 (0.32-2.61)
Investigator-reported hypoglycaemia*
No 11/3048 16/1604 0.39 (0.18-0.86) 0.45 (0.22-0.94)
Yes 0/271 7/316 n.a. 0.58 (0.13-2.58)
Framingham 10-year CV risk score
≤ 15% 4/2395 5/1323 0.50 (0.13-1.90) 0.68 (0.24-1.95)
> 15% 7/923 18/597 0.31 (0.13-0.75) 0.40 (0.18-0.90)
*Exploratory analyses (all others pre-specified analyses).
CI, confidence interval; CMH, Cochran-Mantel-Haenszel; CV, cardiovascular; HR, hazard ratio; n.a., not applicable; RR, risk ratio.
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Page 7 of 10Although the results of the different meta-analyses of
DPP-4 inhibitors are not entirely comparable (due to
differences in primary composite endpoints and CV
adjudication methods), all are supportive of the hypoth-
esis that, in general, DPP-4 inhibitor treatment does not
have a deleterious impact on the incidence of CV
events. The present analysis shows that linagliptin treat-
ment does not increase CV risk and may even yield CV
benefits in patients with T2DM. Meta-analyses of other
DPP-4 inhibitors were frequently retrospective in nature.
However, the pre-specified design of the present meta-
analysis involved prospective and blinded adjudication
of CV events, which should strengthen the validity of
the current findings. In addition, this meta-analysis was
based on individual patient data from a consistently
designed, large clinical development programme; this
allows consistent derivation of endpoints and extensive
subgroup analyses and minimizes between-study hetero-
geneity that can confound analyses of unrelated studies.
There are several mechanisms that could underlie
potential CV benefits for linagliptin. First, linagliptin
may confer the beneficial effects of improved glycaemic
control, including the lowering of postprandial glucose,
without the potentially harmful effects of weight gain or
increased hypoglycaemia [12,26]. Second, linagliptin
increases GLP-1 and GIP levels which may provide ben-
eficial cardioprotection; experimental and clinical data
suggest that GLP-1 elevation can positively modulate
lipid metabolism [26], reduce infarct size and improve
cardiac function [26,27]. Third, DPP-4 substrates
include not only incretins but also vasoactive peptides
involved in inflammation, immunity, and CV function;
some evidence, mainly from preclinical studies, indicates
that reduced DPP-4 activity can lessen inflammation,
stimulate endothelial repair, and blunt ischaemic injury
[28]. Finally, linagliptin holds inherent anti-oxidative
properties, most likely due to its xanthine-based mole-
cular structure [29]. These properties, both directly
through reduction of reactive oxygen species and indir-
ectly through beneficial effects on inflammatory media-
tors and endothelial function, could reduce the
atherosclerotic burden [30].
This analysis has several potential limitations. First,
despite a large total patient exposure of 3432 years, indi-
vidual patient exposure was of a maximum duration of
1.7 years; further longer-term data are needed to con-
firm the current findings. Second, the low incidence of
CV events, low rates of triple oral therapy, and lack of
insulin treatment all suggest that a large proportion of
patients had less advanced T2DM, and thus a lower CV
risk than those with more advanced T2DM. However,
around 30% of patients had a baseline Framingham 10-
year CV risk score of > 15% and more than a half also
had > 5 years’ known disease duration, which indicates
a proportion of the population were at increased CV
risk. Finally, the observed CV risk reductions for the pri-
mary and secondary endpoints were influenced by the
differences in CV events in one study with linagliptin
versus glimepiride. Despite this, it is important to note
that glimepiride is an established and recommended sec-
ond-line therapy with a well-characterized safety profile,
which has not been directly linked to increased CV risk
either as part of intensive treatment regimens or when
compared with other conventional treatments [31].
Moreover, analysis of the pooled placebo studies alone
confirmed that linagliptin did not increase CV risk
against placebo.
Conclusions
In summary, this pre-specified CV meta-analysis of a
large Phase 3 programme that involved prospective and
independent adjudication of CV events provides valuable
new insights on the CV safety profile of linagliptin.
Figure 3 HR estimates for secondary composite CV endpoints
with linagliptin versus total comparators based on Cox hazard
model. CI, confidence interval; CV, cardiovascular; FDA, Food and
Drug Administration; MACE, major adverse CV events; MI, myocardial
infarction.
Table 6 Risk for tertiary individual CV endpoints with
linagliptin versus total comparators based on Cox hazard
model
Cox HR (95% CI)
CV death 0.74 (0.10-5.33)
Non-fatal MI 0.52 (0.17-1.54)
Non-fatal stroke 0.11 (0.02-0.51)
TIA 0.17 (0.02-1.53)
UAP with hospitalization 0.24 (0.02-2.34)
UAP without hospitalization 0.73 (0.04-12.02)
SAP 1.06 (0.44-2.58)
Total mortality 1.02 (0.23-4.63)
CI, confidence interval; CV; cardiovascular; HR, hazard ratio; MI, myocardial
infarction; SAP, stable angina pectoris; TIA, transient ischaemic attack; UAP,
unstable angina pectoris.
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Page 8 of 10Although a meta-analysis, with distinct limitations, the
data indicate that linagliptin does not increase CV risk
and, moreover, support a potential reduction of CV
events with linagliptin compared with pooled compara-
tors. These results suggest that linagliptin may be a
valuable new therapeutic option for improving glycaemic
control in patients with T2DM. The hypothesis that
linagliptin may have CV benefits is currently being
tested prospectively in the CAROLINA study
(NCT01243424), the first large outcomes study to
directly compare a DPP-4 inhibitor versus a sulphony-
lurea (glimepiride), predominantly as second-line ther-
apy (i.e. on a background of metformin).
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